Phaseline

Targets › PB2

PB2: drug programs, companies and trials

1 program from 1 company in 4 trials: 3 Phase 3, 1 Phase 2; Infectious disease, Oncology; next expected readout Apr 2027.

Open in Phaseline: the race on PB2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
RocheBaloxavir marboxil
Polymerase acidic protein inhibitor
INFLAV, PB2Phase 3Influenza, Human; Influenza; Influenza Disease; Flu; Hematopoietic and Lymphoid Cell NeoplasmApr 2027

Conditions

Influenza, Human (1) Influenza (1) Influenza Disease; Flu (1) Hematopoietic and Lymphoid Cell Neoplasm (1)

Modalities

small molecule (1)

Companies

Roche (1)

Related targets

INFLAV (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.